Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $950
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Overweight rating on Eli Lilly (LLY) and increased the price target from $805 to $950. This adjustment reflects a positive outlook on the company's stock.
February 16, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Eli Lilly and raised the price target from $805 to $950, indicating a strong positive outlook on the stock.
The increase in price target by a reputable analyst like Terence Flynn from Morgan Stanley suggests a strong confidence in Eli Lilly's future performance. This is likely to instill positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100